^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | REC-4881 (MEK1 inhibitor, MEK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
Excerpt:
Fifty-four CRC cell lines were exposed to TAK-733, while 42 cell lines were deemed sensitive across a broad range of mutations....Cell lines with a KRAS/NRAS or BRAF mutation were associated with sensitivity to TAK-733 (p = 0.03), and even greater sensitivity was observed in 14 of 17 CRC cell lines that were KRAS/NRAS mutant and PIK3CA wild-type.
DOI:
10.18632/oncotarget.5949
